Blueprint Medicines
BPMC
BPMC was delisted on the 17th of July, 2025.
203 hedge funds and large institutions have $3.89B invested in Blueprint Medicines in 2019 Q1 according to their latest regulatory filings, with 51 funds opening new positions, 66 increasing their positions, 59 reducing their positions, and 10 closing their positions.
410% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 10
60% more capital invested
Capital invested by funds: $2.42B → $3.89B (+$1.46B)
57% more funds holding in top 10
Funds holding in top 10: 7 → 11 (+4)
25% more funds holding
Funds holding: 162 → 203 (+41)
12% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 59
6.03% more ownership
Funds ownership: 104.04% → 110.07% (+6%)
12% less call options, than puts
Call options by funds: $15.1M | Put options by funds: $17.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$30.6M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$26.1M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$25.6M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$21.9M |
| 5 |
MWNA
Marshall Wace North America
New York
|
+$19.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
-$40M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$37.4M |
| 3 |
Morgan Stanley
New York
|
-$15M |
| 4 |
State Street
Boston,
Massachusetts
|
-$14.7M |
| 5 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$13.7M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
201
Rockefeller Capital Management
New York
| $1K | +$1.26K | +17 | New |
|
|
TI
202
Trexquant Investment
Stamford,
Connecticut
| – | -$1.5M | -27,774 | Closed |
|
203
Marshall Wace
London,
United Kingdom
| – | -$466K | -8,635 | Closed |
|
|
WCM
204
Weld Capital Management
New York
| – | -$403K | -7,467 | Closed |
|
205
Group One Trading
Chicago,
Illinois
| – | -$386K | -7,158 | Closed |
|
|
GC
206
Grace Capital
Quincy,
Massachusetts
| – | -$145K | -2,696 | Closed |
|
|
AIM
207
Assured Investment Management
New York
| – | -$57K | -1,059 | Closed |
|
|
GWM
208
Geneos Wealth Management
Englewood,
Colorado
| – | -$7K | -150 | Closed |
|
|
PRC
209
Pearl River Capital
Niles,
Michigan
| – | -$5K | -100 | Closed |
|
|
IA
210
IFP Advisors
Tampa,
Florida
| – | -$1K | -23 | Closed |
|
211
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| – | +$148 | +2 | New |
|
|
VCM
212
Versant Capital Management
Phoenix,
Arizona
| – | +$517 | +7 | New |
|
BPMC Hedge Fund Activity: Q1 2019 in Review
203 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q1 2019, worth a combined $3.89B — up 60% from $2.42B a quarter earlier.
Buyers outnumbered sellers: 51 funds opened new BPMC positions and 10 closed out — a net gain of 41 holders — while 66 added to existing stakes and 59 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $30.6M. The largest seller was Viking Global Investors, cutting an estimated $40M.
- 203 institutional investors held Blueprint Medicines (BPMC) as of Q1 2019, up from 162 in Q4 2018.
- Funds reported $3.89B of Blueprint Medicines stock for Q1 2019, up 60% quarter-over-quarter.
- 51 funds opened new Blueprint Medicines positions in Q1 2019 and 10 closed out, a net change of +41 holders.
- The largest Blueprint Medicines buyer in Q1 2019 was Perceptive Advisors, an estimated $30.6M added.
- The largest Blueprint Medicines seller in Q1 2019 was Viking Global Investors, an estimated $40M sold.
Based on aggregated 13F filings for Q1 2019.